SPARC Receives CRL from USFDA for Latanoprost NDA

01 Aug 2015 Evaluate

Sun Pharma Advanced Research Company (SPARC) has received Complete Response letter (CRL) from U.S. Food and Drug Administration (USFDA) to its New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops. The company has submitted a response to an earlier CRL it had received from the USFDA, wherein no additional preclinical or clinical data was required. While the USFDA has accepted the clarifications and changes to the labeling, company has now received another CRL from the USFDA seeking minor changes to the proposed labeling. The company hopes to address these requirements soon.

This product is to be manufactured at SPIL’s Halol facility and the USFDA has indicated that a satisfactory resolution of the cGMP deficiencies at this facility is a prerequisite for the final approval of Xelpros. SPARC had recently out-licensed this product to a subsidiary of Sun Pharmaceutical Industries (SPIL).

Sun Pharma Advanced Research Company is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

131.10 -1.70 (-1.28%)
17-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 646.20
Indegene 530.55
CMS Info Systems 346.45
Sagility 50.78
Smartworks Coworking 476.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×